Fig. 8From: Microtubule cytoskeleton-disrupting activity of MWCNTs: applications in cancer treatmentTaxol®(paclitaxel) interaction with microtubules and major reported resistance mechanisms. (1) Drug efflux pumps, (2) intracellular drug degradation, (3) tubulin mutations, or posttranslational modifications impeding microtubule-associated drug binding (green arrow)Back to article page